![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves a New Combination Vaccine to Fight Whooping Cough
FDA Approves a New Combination Vaccine to Fight Whooping Cough
June 15, 2005
The FDA has approved sanofi-aventis' Adacel, a new vaccine for a single booster immunization against pertussis (whooping cough), in combination with tetanus and diphtheria.
Approved for use in adolescents and adults ages 11 to 64, Adacel is the first vaccine cleared as a pertussis booster for adults.
Adacel contains the same components as sanofi-aventis' Daptacel, a vaccine indicated for infants and children, but the diphtheria toxoid and one of the pertussis components are in reduced quantities. The FDA approved a similar vaccine -- GlaxoSmithKline's Boostrix -- in May for use in adolescents 10 to 18 years of age.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct